切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2022, Vol. 16 ›› Issue (02) : 116 -120. doi: 10.3877/cma.j.issn.1674-0807.2022.02.009

综述

血小板衍生生长因子/血小板衍生生长因子受体信号通路在乳腺癌发生、发展中的作用
郑鲁丹1, 陈敏2, 张永渠3, 张国君3,()   
  1. 1. 361100 厦门大学医学院内分泌肿瘤精准诊治重点实验室;315000 中国科学院大学宁波华美医院乳腺外科
    2. 361100 厦门大学医学院内分泌肿瘤精准诊治重点实验室
    3. 361100 厦门大学医学院内分泌肿瘤精准诊治重点实验室;361100 厦门大学附属翔安医院肿瘤诊治中心与乳腺甲状腺外科
  • 收稿日期:2020-02-17 出版日期:2022-04-01
  • 通信作者: 张国君

Role of platelet­derived growth factor/platelet­derived growth factor receptor signaling pathway in oncogenesis and progression of breast cancer

Ludan Zheng1, Min Chen2, Yongqu Zhang3   

  • Received:2020-02-17 Published:2022-04-01
引用本文:

郑鲁丹, 陈敏, 张永渠, 张国君. 血小板衍生生长因子/血小板衍生生长因子受体信号通路在乳腺癌发生、发展中的作用[J/OL]. 中华乳腺病杂志(电子版), 2022, 16(02): 116-120.

Ludan Zheng, Min Chen, Yongqu Zhang. Role of platelet­derived growth factor/platelet­derived growth factor receptor signaling pathway in oncogenesis and progression of breast cancer[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2022, 16(02): 116-120.

PDGF/PDGFR信号通路在细胞增殖、血管生成和纤维化中起着重要的作用,被证实在脑胶质瘤、结直肠癌和乳腺癌等多种癌症中亦有促癌作用。其中血小板衍生生长因子(PDGF)-B/血小板衍生生长因子受体(PDGFR)-β与乳腺癌的发生、发展关系密切,在乳腺癌中的表达水平存在组织差异性,而且与雌激素水平和分子分型等有关。PDGF-B/PDGFR-β以自分泌或旁分泌环的形式作用于乳腺肿瘤细胞以及微环境中的基质细胞,除了促进乳腺癌细胞上皮间质转化、增殖和侵袭迁移以外,还能促进肿瘤血管生成。笔者就PDGF-B/PDGFR-β信号通路在乳腺癌发生、发展中的作用进行阐述,并探讨其作为乳腺癌潜在的治疗靶点,未来可能指导乳腺癌个体化治疗。

图1 PDGF/PDGFR信号转导通路注:PDGF为血小板衍生生长因子;PDGFR为血小板衍生生长因子受体;PI3K为磷酯酰肌醇-3激酶;PLC-γ为磷脂酶C-γ;Ras/MAPK为Ras/丝裂原活化蛋白激酶;JAK/STAT为Janus激酶/信号转导与转录激活因子
[1]
Bray F, Ferlay J, Soerjomataram I,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin2018, 68(6):394-424.
[2]
Zheng RS, Sun KX, Zhang SW,et al. Report of cancer epidemiology in China, 2015[J]. Zhonghua Zhong Liu Za Zhi2019, 41(1):19-28.
[3]
Scimeca M, Urbano N, Bonfiglio R,et al. Novel insights into breast cancer progression and metastasis: A multidisciplinary opportunity to transition from biology to clinical oncology[J]. Biochim Biophys Acta Rev Cancer2019, 1872(1):138-148.
[4]
Papadopoulos N, Lennartsson J. The PDGF/PDGFR pathway as a drug target[J]. Mol Aspects Med2018, 62:75-88.
[5]
Jitariu AA, Raica M, Cimpean AM,et al. The role of PDGF-B/PDGFR-BETA axis in the normal development and carcinogenesis of the breast[J]. Crit Rev Oncol Hematol2018, 131:46-52.
[6]
Ross R, Glomset J, Kariya B,et al. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro[J]. Proc Natl Acad Sci U S A1974, 71(4):1207-1210.
[7]
Kazlauskas A. PDGFs and their receptors[J]. Gene2017, 614:1-7.
[8]
Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms[J]. Cytokine Growth Factor Rev2004, 15(4):197-204.
[9]
Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine[J]. Genes Dev2008, 22(10):1276-1312.
[10]
Sil S, Periyasamy P, Thangaraj A,et al. PDGF/PDGFR axis in the neural systems[J]. Mol Aspects Med2018, 62:63-74.
[11]
Bessonnard S, Vandormael-Pournin S, Coqueran S,et al. PDGF signaling in primitive endoderm cell survival is mediated by PI3K-mTOR through p53-independent mechanism[J]. Stem Cells2019, 37(7):888-898.
[12]
Tannenberg P, Chang YT, Muhl L,et al.Extracellular retention of PDGF-B directs vascular remodeling in mouse hypoxia-induced pulmonary hypertension[J]. Am J Physiol Lung Cell Mol Physiol2018, 314(4):L593-L605.
[13]
Su M, Yue Z, Wang H,et al. Ufmylationis activated in vascular remodeling and lipopolysaccharide-induced endothelial cell injury[J]. DNA Cell Biol2018, 37(5):426-431.
[14]
Dadrich M, Nicolay NH, Flechsig P,et al. Combined inhibition of TGF beta and PDGF signaling attenuates radiation-induced pulmonary fibrosis[J]. Oncoimmunology2015, 5(5):e1123366.
[15]
Klinkhammer BM, Floege J, Boor P. PDGF in organ fibrosis[J]. Mol Aspects Med2018, 62:44-62.
[16]
Wang Y, Appiah-Kubi K, Wu M,et al. The platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) are major players in oncogenesis, drug resistance, and attractive oncologic targets in cancer[J]. Growth Factors2016, 34(1/2):64-71.
[17]
Östman A. PDGF receptors in tumor stroma: Biological effects and associations with prognosis and response to treatment[J]. Adv Drug Deliv Rev2017, 121:117-123.
[18]
Appiah-Kubi K, Lan T, Wang Y,et al. Platelet-derived growth factor receptors (PDGFRs) fusion genes involvement in hematological malignancies[J]. Crit Rev Oncol Hematol2017, 109:20-34.
[19]
Sharma VK, Singh A, Srivastava SK,et al. Increased expression of platelet-derived growth factor associated protein-1 is associated with PDGF-B mediated glioma progression[J]. Int J Biochem Cell Biol2016, 78:194-205.
[20]
Manzat Saplacan RM, Balacescu L, Gherman C,et al. Therole of PDGFs and PDGFRs in colorectal cancer[J]. Mediators Inflamm2017, 2017:4708076.
[21]
Qian H, Appiah-Kubi K, Wang Y,et al. The clinical significance of platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) in gastric cancer: A systematic review and meta-analysis[J]. Crit Rev Oncol Hematol2018, 127:15-28.
[22]
Bartoschek M, Pietras K. PDGF family function and prognostic value in tumor biology[J]. Biochem Biophys Res Commun2018, 503(2):984-990.
[23]
王媚媚,秦晓红,米立志. 血小板衍生生长因子受体结构与功能的研究[J]. 中国科学:生命科学2019, 49(6):683-697.
[24]
Slattery ML, John EM, Stern MC,et al. Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study[J]. Breast Cancer Res Treat2013, 140(3):587-601.
[25]
Bronzert DA, Bates SE, Sheridan JP,et al. Transforming growth factor-beta induces platelet-derived growth factor (PDGF) messenger RNA and PDGF secretion while inhibiting growth in normal human mammary epithelial cells[J]. Mol Endocrinol1990, 4(7):981-989.
[26]
Coltrera MD, Wang J, Porter PL,et al. Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma[J]. Cancer Res1995, 55(12):2703-2708.
[27]
Feakins RM, Wells CA, Young KA,et al. Platelet-derived growth factor expression in phyllodes tumors and fibroadenomas of the breast[J]. Hum Pathol2000, 31(10):1214-1222.
[28]
Sistigu A, Di Modugno F, Manic G,et al. Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting[J]. Cytokine Growth Factor Rev2017, 36:67-77.
[29]
Frings O, Augsten M, Tobin NP,et al. Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling[J]. Am J Pathol2013, 182(6):2037-2047.
[30]
Jechlinger M, Sommer A, Moriggl R,et al. Autocrine PDGFR signaling promotes mammary cancer metastasis[J]. J Clin Invest2006, 116(6):1561-1570.
[31]
Kadivar A, Kamalidehghan B, Akbari Javar H,et al. Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-beta, PDGF-BB, c-Kit and SCF genes[J]. Drug Des Devel Ther2017, 11:469-481.
[32]
Zhang Y, Zhao Y, Li L,et al. The oncoprotein HBXIP upregulates PDGFB via activating transcription factor Sp1 to promote the proliferation of breast cancer cells[J]. Biochem Biophys Res Commun2013, 434(2):305-310.
[33]
Yokoyama Y, Mori S, Hamada Y,et al. Platelet-derived growth factor regulates breast cancer progression via beta-catenin expression[J]. Pathobiology2011, 78(5):253-260.
[34]
Primac I, Maquoi E, Blacher S,et al. Stromal integrin alpha11 regulates PDGFR-beta signaling and promotes breast cancer progression[J]. J Clin Invest2019129(11):4609-4628.
[35]
Zhang Y, He W, Zhang S. Seeking forcorrelative genes and signaling pathways with bone metastasis from breast cancer by integrated analysis[J]. Front Oncol2019, 9:138.
[36]
Ribatti D. Endogenous inhibitors of angiogenesis: a historical review[J]. Leuk Res2009, 33(5):638-644.
[37]
Folkman J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med1971, 285(21):1182-1186.
[38]
Zuazo-Gaztelu I, Casanovas O. Unraveling therole of angiogenesis in cancer ecosystems[J]. Front Oncol2018, 8:248.
[39]
Jin S, Yang C, Huang J,et al. Conditioned medium derived from FGF-2-modified GMSCs enhances migration and angiogenesis of human umbilical vein endothelial cells[J]. Stem Cell Res Ther2020, 11(1):68.
[40]
Gianni-Barrera R, Butschkau A, Uccelli A,et al. PDGF-BB regulates splitting angiogenesis in skeletal muscle by limiting VEGF-induced endothelial proliferation[J]. Angiogenesis2018, 21(4):883-900.
[41]
Ding X, Xi W, Ji J,et al. HGF derived from cancer-associated fibroblasts promotes vascularization in gastric cancer via PI3K/AKT and ERK1/2 signaling[J]. Oncol Rep2018, 40(2):1185-1195.
[42]
Thijssen VL, Paulis YW, Nowak-Sliwinska P,et al. Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth[J]. J Pathol2018, 246(4):447-458.
[43]
Guo P, Hu B, Gu W, et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment[J]. Am J Pathol2003162(4):1083-1093.
[44]
Gialeli C, Nikitovic D, Kletsas D,et al. PDGF/PDGFR signaling and targeting in cancer growth and progression: Focus on tumor microenvironment and cancer-associated fibroblasts[J]. Curr Pharm Des2014, 20(17):2843-2848.
[45]
Pinto MP, Dye WW, Jacobsen BM,et al. Malignant stroma increases luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signaling[J]. BMC Cancer2014, 14:735.
[46]
Czekierdowska S, Stachowicz N, Chrós'ciel M,et al. Proliferation and maturation of intratumoral blood vessels in women with malignant ovarian tumors assessed with cancer stem cells marker nestin and platelet derived growth factor PDGF-B[J]. Ginekol Pol2017, 88(3):120-128.
[47]
Vrekoussis T, Stathopoulos EN, Kafousi M,et al. Expression of endothelial PDGF receptors alpha and beta in breast cancer: up-regulation of endothelial PDGF receptor beta[J]. Oncol Rep2007, 17(5):1115-1119.
[48]
Wagner KD, Du S, Martin L,et al. Vascular PPAR beta/delta promotes tumor angiogenesis and progression[J]. Cells2019, 8(12):1623.
[49]
Hsu YL, Yen MC, Chang WA,et al. CXCL17-derived CD11b(+)Gr-1(+) myeloid-derived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB[J]. Breast Cancer Res2019, 21(1):23.
[50]
Raica M, Cimpean AM. Platelet-derived growth factor (PDGF)/PDGF receptors (PDGFR) axis as target for antitumor and antiangiogenic therapy[J]. Pharmaceuticals (Basel)2010, 3(3):572-599.
[51]
Lev DC, Kim SJ, Onn A,et al. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice[J]. Clin Cancer Res2005, 11(1):306-314.
[52]
Roskoski R Jr. The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders[J]. Pharmacol Res2018, 129:65-83.
[53]
Waller CF. Imatinibmesylate[J]. Recent Results Cancer Res2018, 212:1-27.
[54]
Cristofanilli M, Morandi P, Krishnamurthy S,et al. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations[J]. Ann Oncol2008, 19(10):1713-1719.
[55]
Yang L, Li N, Xue Z,et al. Synergistic therapeutic effect of combined PDGFR and SGK1 inhibition in metastasis-initiating cells of breast cancer[J]. Cell Death Differ2020, 27(7):2066-2080.
[56]
Watanabe T, Koyama N. Preclinical study for antitumor mechanism of lenvatinib and clinical studies for hepatocellular carcinoma[J]. Nihon Yakurigaku Zasshi2019, 153(5):242-248.
[57]
Yam C, Murthy RK, Rauch GM,et al. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-beta[J]. Invest New Drugs2018, 36(6):1103-1109.
[58]
Paulsson J, Ryden L, Strell C,et al. High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer[J]. J Pathol Clin Res2016, 3(1):38-43.
[59]
Zhang X, Blaskovich MA, Forinash KD,et al. Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours[J]. Br J Cancer2014, 111(5):894-902.
[60]
Kaplan CD, Kruger JA, Zhou H,et al. A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma[J]. Vaccine2006, 24(47/48):6994-7002.
[61]
Wang JC, Li GY, Wang B,et al. Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation[J]. J Exp Clin Cancer Res2019, 38(1):235.
[62]
Oliveira C, Granja S, Neves NM,et al. Fucoidan from fucus vesiculosus inhibits new blood vessel formation and breast tumor growth in vivo[J]. Carbohydr Polym2019, 223:115 034.
[63]
Meng YQ, Zhou Y, Li QW,et al. Synthesis of oleanolic acid analogues targeting PDGF receptor inhibitors and their antitumor biological activities[J]. J Asian Nat Prod Res2021, 23(2):150-162.
[1] 郝玥萦, 毛盈譞, 张羽, 汪佳旭, 韩林霖, 匡雯雯, 孟瑶, 杨秀华. 超声引导衰减参数成像评估肝脂肪变性及其对心血管疾病风险的预测价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 770-777.
[2] 曹雯佳, 刘学兵, 罗安果, 钟释敏, 邓岚, 王玉琳, 李赵欢. 超声矢量血流成像对2型糖尿病患者颈动脉壁剪切应力的研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(07): 709-717.
[3] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[4] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[5] 杨成鹏. 以旋股外侧动脉前支为蒂的股前外侧皮瓣临床应用研究[J/OL]. 中华损伤与修复杂志(电子版), 2025, 20(01): 92-92.
[6] 王卫东. 贲门周围血管离断与左膈下静脉的保留[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 464-464.
[7] 吴晖, 佴永军, 施雪松, 魏晓为. 两种解剖入路下行直肠癌侧方淋巴结清扫的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 40-43.
[8] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[9] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[10] 王学虎, 赵渝. 复杂腹壁疝手术中血管损伤并发症的预防和处理[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 616-619.
[11] 周正阳, 陈凯, 仇多良, 邵乐宁, 吴浩荣, 钟丰云. 腹腔镜腹股沟疝修补术后出血原因分析及处理[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 660-664.
[12] 朱佳琳, 方向, 贵诗雨, 黄丹, 周小雨, 郭文恺. 大鼠切口疝腹膜前间隙补片修补术后血清中VEGF 和Ang-1 的表达情况[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 703-707.
[13] 石佳娜, 钱琳艳, 姬凯悦, 祁金文, 胡情, 孙佳斌. 从PVAT 白色脂肪棕色化角度探讨中药在防治动脉粥样硬化中的应用[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 853-858.
[14] 李金星, 陈志宏, 孙铭均, 孙岩岩, 党树伟, 李广恩, 彭书奇, 付大伟, 李宏伟, 李国东. 基于多层螺旋CT 的腹腔干解剖变异与新分型研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 756-763.
[15] 张家珺, 张海涛, 苏菲菲. 径向壁应变分析在冠心病诊疗中的应用[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 687-691.
阅读次数
全文


摘要